XML 68 R40.htm IDEA: XBRL DOCUMENT v3.25.4
Description of Operations and Summary of Significant Accounting Policies - Description of Operations (Details)
$ in Billions
12 Months Ended
Dec. 31, 2025
USD ($)
Customer
Dec. 31, 2024
Customer
Dec. 31, 2023
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Capitalized fees paid, estimated useful life 15 years    
Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer One      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration Risk, Percentage 24.00% 31.00% 31.00%
Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Two      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration Risk, Percentage 22.00% 24.00% 27.00%
Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Three      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration Risk, Percentage 22.00% 24.00% 27.00%
Product [Member]      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Number of major customers | Customer 3 3  
Product [Member] | Customer Concentration Risk | Receivables from Net Product Sales | Customer One      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration Risk, Percentage 29.00% 31.00%  
Product [Member] | Customer Concentration Risk | Receivables from Net Product Sales | Customer Two      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration Risk, Percentage 28.00% 18.00%  
Product [Member] | Customer Concentration Risk | Receivables from Net Product Sales | Customer Three      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Concentration Risk, Percentage 16.00% 15.00%  
Sarissa Capital      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Percentage of common stock owned by a related party   11.60%  
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Royalty rate for first level of annual global net sales (as a percent) 15.00%    
Annual global sales level used to determine royalty rate | $ $ 3.0    
Royalty rate for sales above first level of annual global net sales (as a percent) 5.00%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Royalty rate for combination products (as a percent) 6.50%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum      
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Royalty rate for combination products (as a percent) 10.00%